indazoles has been researched along with pyrimidinones in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 18 (81.82) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Bellamacina, C; Gesner, TG; Jia, W; Lin, S; Lindvall, M; Shafer, CM; Walter, A; Yabannavar, A | 1 |
| Andreeff, M; Jin, L; Kimura, S; Konopleva, M; Miida, T; Raffeld, M; Shikami, M; Tabe, Y | 1 |
| Hoshino, D; Maldonado, AT; Tyson, DR; Weaver, AM; Wirtz, ED | 1 |
| Buijsman, RC; de Man, J; de Roos, JA; de Vetter, JR; Prinsen, MB; Spijkers-Hagelstein, JA; Uitdehaag, JC; van Doornmalen, AM; Zaman, GJ | 1 |
| Ahmed, SR; Ball, DW; Bhan, S; Clark, DP; Jin, N; Nelkin, BD; Rosen, DM; Schayowitz, A; Xue, P | 1 |
| Cox, AD; Der, CJ; Finn, AJ; Pedone, KH; Ryan, MB; Thomas, NE | 1 |
| Booth, L; Dent, P; Kirkwood, JM; Lee, J; Poklepovic, A; Roberts, JL; Sander, C | 1 |
| Endo, M; Fukushi, JI; Fukushima, S; Hatano, M; Iwamoto, Y; Matsumoto, Y; Matsunobu, T; Nabeshima, A; Okada, S; Yokoyama, N | 1 |
| Azad, NS; Gallagher, D; O'Connor, A; Ohaji, C; Rosner, G; Sartorius-Mergenthaler, S; Shroff, RT; Subbiah, V; Yarchoan, M; Zahurak, ML; Zinner, R | 1 |
| Bhutkar, A; Chen, PY; Chung, KM; Dorans, KJ; Hong, E; Jacks, T; Muzumdar, MD; Noll, EM; Sprick, MR; Trumpp, A | 1 |
| Dang, KX; Haglund, C; Ho, TH; Koistinen, H; Lintula, S; Mustonen, H; Räsänen, K; Stenman, J; Stenman, UH | 1 |
| Ahn, NG; Basken, J; Ebmeier, CC; Kavran, AJ; Lee, T; Old, WM; Stuart, SA | 1 |
| Buclin, T; Cagnon, L; Cardoso, E; Csajka, C; Decosterd, L; Diezi, M; Ellefsen-Lavoie, K; Homicsko, K; Mercier, T; Michielin, O; Wagner, AD; Widmer, N | 1 |
| Corrie, P; Danson, S; Goff, M; Love, SB; Marshall, E; Mauch, C; Middleton, MR; Mohammed, SB; Plummer, E; Schadendorf, D; Scudder, C; Urbonas, V; Wheater, M; Zimmer, L | 1 |
| Kirkwood, JM; Massa, RC | 1 |
| Ahmed, S; Azad, NS; Ball, DW; Bishop, JA; Gocke, CD; Ha, Y; Karunsena, E; Kurzrock, R; Nelkin, BD; O'Connor, A; Parkinson, RM; Rudek, MA; Sharma, R; Sherman, SI; Subbiah, V; Zahurak, ML; Zinner, R | 1 |
| Bedoni, N; Bucher, M; El Zaoui, I; Kaya, G; Leyvraz, S; Moulin, AP; Nicolas, M; Pescini Gobert, R; Riggi, N; Rimoldi, D; Rivolta, C; Sakina, E; Schalenbourg, A; Zografos, L | 1 |
| Creixell, P; Jeschke, GR; Kim, J; Linding, R; Longden, J; Poulikakos, PI; Rosen, N; Santini, CC; Schoof, EM; Simpson, CD; Turk, BE; Wu, X | 1 |
| Berger, MF; Cocco, E; Cownie, J; de Stanchina, E; Drilon, A; Ebata, K; Guzman, S; Hechtman, JF; Houck-Loomis, B; Hyman, DM; Kulick, A; Ladanyi, M; Lanman, RB; Mattar, M; Misale, S; Nagy, RJ; Patel, JA; Ptashkin, R; Razavi, P; Samoila, A; Scaltriti, M; Schram, AM; Selçuklu, SD; Shifman, S; Somwar, R; Toska, E; Tuch, BB; Won, HH; Yaeger, R | 1 |
| Bartlett, DL; Choudry, HA; Dilly, A; Honick, BD; Lee, YJ | 1 |
| Bridges, KA; Clump, DA; Faust, AZ; Ferris, RL; Frederick, MJ; Heffernan, TP; Mason, KA; Meyn, RE; Molkentine, DP; Molkentine, JM; Myers, JN; Pickering, CR; Sheth, A; Skinner, HD; Xie, T; Yang, L | 1 |
| Kleszcz, R; Paluszczak, J | 1 |
2 trial(s) available for indazoles and pyrimidinones
| Article | Year |
|---|---|
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Indazoles; Male; Melanoma; Middle Aged; Mutation; Paclitaxel; Prognosis; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides; Survival Rate | 2019 |
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrimidinones; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2019 |
20 other study(ies) available for indazoles and pyrimidinones
| Article | Year |
|---|---|
4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
Topics: Binding Sites; Caco-2 Cells; Cell Cycle Proteins; Chemistry, Pharmaceutical; Drug Design; Enzyme Inhibitors; Humans; Indazoles; Inhibitory Concentration 50; Models, Chemical; Molecular Conformation; Molecular Structure; Protein Serine-Threonine Kinases; Pyrimidinones; Structure-Activity Relationship | 2008 |
Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.
Topics: Cell Cycle; Cell Proliferation; Chromones; Humans; Indazoles; Lymphoma, Mantle-Cell; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidinones; Sulfonamides | 2014 |
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Topics: Benzoquinones; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Imidazoles; Indazoles; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Pyridones; Pyrimidinones; Quinolines; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2015 |
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aza Compounds; Benzimidazoles; beta Catenin; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Melanoma; Molecular Targeted Therapy; Mutation; Oxazoles; Oximes; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Quinolines; Sulfonamides; Triazoles; Vemurafenib | 2015 |
Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indazoles; MAP Kinase Signaling System; Mice, Nude; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides; Thyroid Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.
Topics: Animals; Cell Line, Tumor; Cell Movement; Female; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Guanine Nucleotide Exchange Factors; Humans; Indazoles; Indoles; Male; MAP Kinase Signaling System; Melanoma; Membrane Proteins; Mice; Mutation; Piperazines; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sulfonamides; Up-Regulation; Vemurafenib | 2016 |
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagosomes; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Male; Melanoma; Mice, Nude; Microscopy, Fluorescence; Oximes; Phenylbutyrates; Pyridones; Pyrimidines; Pyrimidinones; RNA Interference; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2017 |
Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
Topics: Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 6; Female; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridones; Pyrimidines; Pyrimidinones; ras Proteins; Sarcoma, Synovial; Sulfonamides | 2017 |
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Disease Progression; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Humans; Hypertension; Indazoles; Male; MAP Kinase Kinase Kinases; Middle Aged; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrimidinones; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Survival Rate; Thrombocytopenia | 2017 |
Survival of pancreatic cancer cells lacking KRAS function.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; DNA Copy Number Variations; Humans; Immunoblotting; Indazoles; Mice; Morpholines; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Purines; Pyrimidines; Pyrimidinones; Quinazolinones; Sulfonamides; Thiazoles | 2017 |
MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Topics: Activating Transcription Factor 4; Adenocarcinoma; Aged; Caco-2 Cells; Cell Line, Tumor; Cohort Studies; Colorectal Neoplasms; Female; HT29 Cells; Humans; Indazoles; Male; Middle Aged; Mitogen-Activated Protein Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Trypsin Inhibitor, Kazal Pancreatic | 2018 |
Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells.
Topics: Cell Line, Tumor; Humans; Indazoles; Melanoma; Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction | 2018 |
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Administration, Oral; Antineoplastic Agents; Azetidines; Child; Chromatography, High Pressure Liquid; Humans; Imidazoles; Indazoles; Indoles; Limit of Detection; Linear Models; Oximes; Phenylurea Compounds; Piperidines; Pyridines; Pyridones; Pyrimidines; Pyrimidinones; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry; Vemurafenib | 2018 |
Targeting the MAPK pathway in advanced BRAF wild-type melanoma.
Topics: Humans; Indazoles; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides | 2019 |
Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Blotting, Western; Conjunctival Neoplasms; Female; Fluorescent Antibody Technique, Indirect; Humans; Imidazoles; Indazoles; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Quinolines; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2019 |
Global view of the RAF-MEK-ERK module and its immediate downstream effectors.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Oximes; Phosphorylation; Piperazines; Proteome; Proteomics; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms | 2019 |
Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Topics: Adolescent; Adult; Animals; Benzamides; Cell Proliferation; Cell-Free Nucleic Acids; Child; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Heterografts; Humans; Imidazoles; Indazoles; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Neoplasms; Oncogene Proteins, Fusion; Oximes; Protein Kinase Inhibitors; Pyrazoles; Pyridones; Pyrimidines; Pyrimidinones; Receptor, trkA; Young Adult | 2019 |
Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Appendix; Cell Line, Tumor; Chemotherapy, Adjuvant; Colon; Colonic Neoplasms; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Indazoles; Intestinal Mucosa; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Mucin-2; Mutation; Neoplasms, Cystic, Mucinous, and Serous; Phosphatidylinositol 3-Kinases; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; DNA Damage; Head and Neck Neoplasms; Humans; Indazoles; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazoles; Pyrimidinones; Radiation Tolerance | 2021 |
The Wnt Signaling Pathway Inhibitors Improve the Therapeutic Activity of Glycolysis Modulators against Tongue Cancer Cells.
Topics: Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxyglucose; Glucose; Glycolysis; Head and Neck Neoplasms; Humans; Indazoles; Pyrimidinones; Tongue; Tongue Neoplasms; Wnt Signaling Pathway | 2022 |